View Older Stories View More Recent Stories

Jan 3, 2024 07:04AM Esperion (ESPR) and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Jan 3, 2024 07:00AM Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Dec 18, 2023 08:00AM Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Dec 13, 2023 04:00PM Esperion Therapeutics (ESPR) Announces FDA Updated LDL-C Lowering Indication for Esperion’s NEXLETOL Tablet and NEXLIZET Tablet
Dec 13, 2023 04:00PM U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
Nov 13, 2023 10:32AM Esperion Therapeutics (ESPR) Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk
Nov 13, 2023 10:30AM Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
Nov 11, 2023 11:00AM Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
Nov 9, 2023 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 7, 2023 06:00AM Esperion Reports Third Quarter 2023 Financial Results
Oct 31, 2023 08:00AM Esperion to Participate in Jefferies London Healthcare Conference
Oct 24, 2023 08:00AM Esperion to Report Third Quarter 2023 Financial Results on November 7
Aug 28, 2023 08:00AM Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Aug 28, 2023 05:09AM Esperion Therapeutics (ESPR) Presents Two CLEAR Outcomes Study Late-Breakers
Aug 26, 2023 11:00AM Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
Aug 11, 2023 08:00AM Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
Aug 8, 2023 04:15PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 1, 2023 06:00AM Esperion Reports Second Quarter 2023 Financial Results
Jul 24, 2023 08:00AM Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
Jul 17, 2023 06:00AM Esperion to Report Second Quarter 2023 Financial Results on August 1
Jul 7, 2023 08:00AM Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
Jun 28, 2023 08:06AM Esperion Therapeutics (ESPR) Announces Submission of Application for Expanded Indication with EMA for NILEMDO Tablet and NUSTENDI Tablet
Jun 28, 2023 08:00AM Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Table
Jun 24, 2023 02:30PM Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
Jun 15, 2023 02:31PM Esperion Therapeutics (ESPR) Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO
Jun 15, 2023 02:30PM Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Jun 8, 2023 08:00AM Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
Jun 5, 2023 08:00AM Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
Jun 1, 2023 08:00AM Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
May 25, 2023 04:30PM Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
May 24, 2023 08:00AM Esperion to Participate in Jefferies Healthcare Conference
May 12, 2023 04:30PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 9, 2023 07:00AM Esperion Reports First Quarter 2023 Financial Results
May 4, 2023 08:30AM Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
May 1, 2023 08:00AM Esperion to Participate in JMP Securities Life Sciences Conference
May 1, 2023 08:00AM Esperion to Participate in JMP Securities Life Sciences Conference
Apr 27, 2023 08:00AM Esperion to Participate in Bank of America Securities 2023 Health Care Conference
Apr 27, 2023 08:00AM Esperion to Participate in Bank of America Securities 2023 Health Care Conference
Apr 25, 2023 08:00AM Esperion to Report First Quarter 2023 Financial Results May 9, 2023
Apr 25, 2023 08:00AM Esperion to Report First Quarter 2023 Financial Results May 9, 2023
Apr 19, 2023 08:42AM Esperion Therapeutics (ESPR) Enters Co-Promotion Agreement With Currax Pharmaceuticals
Apr 19, 2023 08:42AM Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
Apr 19, 2023 08:42AM Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
Apr 3, 2023 08:00AM Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
Apr 3, 2023 08:00AM Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
Mar 22, 2023 04:15PM Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 22, 2023 04:15PM Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 20, 2023 08:00AM Esperion Therapeutics (ESPR) Prices 33.17M Share Offering at $1.675/sh
Mar 20, 2023 08:00AM Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 20, 2023 08:00AM Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
View More Recent Stories View Older Stories